Adc Therapeutics SA (NYSE: ADCT) on Friday, plunged -5.54% from the previous trading day, before settling in for the closing price of $3.25. Within the past 52 weeks, ADCT’s price has moved between $1.05 and $3.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 1.38% over the past five years. The company achieved an average annual earnings per share of 6.42%. With a float of $88.15 million, this company’s outstanding shares have now reached $112.50 million.
Adc Therapeutics SA (ADCT) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Adc Therapeutics SA is 21.65%, while institutional ownership is 59.29%. The most recent insider transaction that took place on Dec 11 ’24, was worth 304,500. In this transaction 10% Owner of this company bought 100,000 shares at a rate of $3.04, taking the stock ownership to the 15,666,731 shares. Before that another transaction happened on Dec 11 ’24, when Company’s 10% Owner bought 100,000 for $3.04, making the entire transaction worth $304,500. This insider now owns 13,145,712 shares in total.
Adc Therapeutics SA (ADCT) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.42 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.39) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.43% during the next five years compared to 1.38% growth over the previous five years of trading.
Adc Therapeutics SA (NYSE: ADCT) Trading Performance Indicators
Adc Therapeutics SA (ADCT) is currently performing well based on its current performance indicators. A quick ratio of 4.66 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.57, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.31 in one year’s time.
Technical Analysis of Adc Therapeutics SA (ADCT)
Adc Therapeutics SA (NYSE: ADCT) saw its 5-day average volume 0.54 million, a negative change from its year-to-date volume of 0.59 million. As of the previous 9 days, the stock’s Stochastic %D was 60.29%.
During the past 100 days, Adc Therapeutics SA’s (ADCT) raw stochastic average was set at 69.18%, which indicates a significant increase from 59.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.17 in the past 14 days, which was lower than the 0.21 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.97, while its 200-day Moving Average is $2.21. Nevertheless, the first resistance level for the watch stands at $3.19 in the near term. At $3.31, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.37. If the price goes on to break the first support level at $3.01, it is likely to go to the next support level at $2.95. Assuming the price breaks the second support level, the third support level stands at $2.83.
Adc Therapeutics SA (NYSE: ADCT) Key Stats
Market capitalization of the company is 345.37 million based on 112,499K outstanding shares. Right now, sales total 70,840 K and income totals -157,850 K. The company made 18,840 K in profit during its latest quarter, and -56,650 K in sales during its previous quarter.
